centis, compared with four for the control group. "When a company is valued at $1 billion at a phase 2 trial, the expectations are quite high," said Gbola Amusa, an analyst at Chardan Capital Markets in New York who has a neutral rating on the stock. Of the 21 patients who received the drug, 42.9 percent ha

centis, compared with four for the control group. "When a company is valued at $1 billion at a phase 2 trial, the expectations are quite high," said Gbola Amusa, an analyst at Chardan Capital Markets in New York who has a neutral rating on the stock. Of the 21 patients who received the drug, 42.9 percent ha